Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 22 for:    dihydroergotamine
Previous Study | Return to List | Next Study

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine (ASCEND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04406649
Recruitment Status : Recruiting
First Posted : May 28, 2020
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
Satsuma Pharmaceuticals, Inc.

Brief Summary:
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.

Condition or disease Intervention/treatment Phase
Migraine Migraine With Aura Migraine Without Aura Drug: Dihydroergotamine Phase 3

Detailed Description:
The ASCEND trial is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Actual Study Start Date : September 14, 2020
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2021


Arm Intervention/treatment
Experimental: STS101
STS101 (dihydroergotamine nasal powder)
Drug: Dihydroergotamine
Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Other Name: Dihydroergotamine Mesylate




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Up to 12 months ]
    Incidence of adverse events, incidence of abnormal physical examination findings, abnormal 12-lead ECG readings and incidence of nasal symptoms.


Secondary Outcome Measures :
  1. Pain Freedom [ Time Frame: Up to 48 hours post-dosing ]
    Proportion of subjects free from headache pain (defined as moderate or severe headache pain becoming none on a 4-point scale)

  2. Freedom From Most-Bothersome Symptom [ Time Frame: Up to 48 hours post-dosing ]
    Proportion of subjects free from most bothersome symptom (MBS) among photophobia, phonophobia and nausea



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Males or females, 18-65 years of age at the time of Screening Visit
  • Subject has at least 1-year history of migraines (with or without aura), according to the
  • International Classification of Headache Disorder, 3rd Edition (ICHD3)

Key Exclusion Criteria:

  • Pregnant or breast-feeding women
  • Women of child-bearing potential not using or not willing to use highly effective contraception.
  • Diagnosis of headache conditions other than migraine with or without aura, including diagnosis of basilar or hemiplegic migraines or cluster headache.
  • History of coronary artery disease, coronary artery vasospasm (including Printz-metals' angina), clinically significant arrhythmia or, peripheral vascular disease, ischemic disease (e.g. Raynaud's syndrome, ischemic bowel syndrome, angina pectoris, myocardial infarction, or documented silent ischemia); percutaneous coronary intervention, or cardiac surgery.
  • History of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, subarachnoid hemorrhage.
  • Diagnosis of major depression with current symptoms, psychosis, alcohol abuse or dependence, drug abuse or dependence, major psychiatric conditions (e.g. schizophrenia, psychosis or Bipolar disorder), dementia. Other significant neurological or psychiatric disorders (including other pain syndromes or risk of suicide) that in the opinion of the investigator might interfere with study participation and assessments or subject safety.
  • Any clinically significant symptoms or conditions, including but not limited to central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions or history of such conditions that, in the opinion of the investigator might interfere with study assessments or safety of participant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04406649


Contacts
Layout table for location contacts
Contact: Clinical Trial Manager 6508370799 clin.inquiries@satsumarx.com

Locations
Show Show 39 study locations
Sponsors and Collaborators
Satsuma Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Chair: Detlef Albrecht, MD Satsuma Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Satsuma Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04406649    
Other Study ID Numbers: STS101-003
First Posted: May 28, 2020    Key Record Dates
Last Update Posted: June 9, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Satsuma Pharmaceuticals, Inc.:
dihydroergotamine
dihydroergotamine mesylate
migraine
Additional relevant MeSH terms:
Layout table for MeSH terms
Dihydroergotamine
Migraine Disorders
Migraine without Aura
Migraine with Aura
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vasoconstrictor Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents